A number of studies have reported that S-1 monotherapy is effective against gastric cancer, with response rates ranging from 26 to 53% (Horikoshi et al, 1996; Sakata et al, 1998; Koizumi et al, 2000; Chollet et al, 2003). This evidence concerns the gene PSMD1 and gastric cancer.